Compound library / Longevity & metabolic / Longevity / Cytoprotective

Humanin

Mitochondrial-derived peptide studied for cytoprotective and anti-apoptotic effects.

CategoryLongevity / Cytoprotective
Regulatory standingNo approved product cited
Typical routeSubcutaneous
Half-lifeShort, minutes
Common dose rangeResearch-stage, not well standardized
Typical cycle lengthNot well established

BioHack Track models Humanin at a half-life of 0.5 hours, so every dose you log is decayed against that curve and the app shows estimated active levels — not just what you typed.

No approved product cited

No FDA-approved product for this compound is cited on this page, and no approved human dose is quoted. Treat the range below as research and community practice rather than a prescribed dose.

Reconstitution

Reconstitute with bacteriostatic water.

Storage

Refrigerate after reconstitution.

Cautions

Primarily preclinical/animal research; human dosing not well established.

Track Humanin in BioHack Track. Half-life, dose range and route come pre-filled from this library — log a dose and the app counts your vial down, models what is in your system, and puts it on the same chart as your labs and body composition.

Others in Longevity / Cytoprotective

What the evidence says

Evidence Check asks 10 questions about every compound. For Humanin it can answer 2 of them, from the papers we hold — graded by how strong the study design is, not by whether the findings are flattering. These are the same verdicts the app gives.

Some Clinical EvidenceInflammation

Clinical trials in humans have looked at this.

  • Redox-sensitive miRNAs and Humanin could mediate effects of exercise and astaxanthin on oxidative stress and inflammation in type 2 diabetesRandomized Controlled Trial · Sci Rep · 2025 · PMID 41249265
Insufficient EvidenceCognition

Only reviews or early work — not enough to say either way.

  • The neuroprotective role of Humanin in Alzheimer's disease: The molecular effectsReview · Eur J Pharmacol · 2025 · PMID 40090538
  • Roles of humanin and derivatives on the pathology of neurodegenerative diseases and cognitionReview · Biochim Biophys Acta Gen Subj · 2022 · PMID 35104624
  • Humanin signal for Alzheimer's diseaseReview · J Alzheimers Dis · 2011 · PMID 21335658

Look up the research

These open a search of each database for Humanin — they are not citations, and nothing here is evidence for any particular dose. The same links are in the app.

Work it out

Selected published studies

8 papers naming Humanin in the title, drawn from PubMed and limited to reviews, meta-analyses and trials. Each was checked against PubMed’s own record for its title, journal and year. This is a starting point, not an evidence review — nothing here is offered as support for the dose range above, and the list is not exhaustive. See the editorial policy.

Where these figures come from

The half-life, route and dose range on this page are compiled from published pharmacokinetic literature, manufacturer and product monographs where one exists, and the ranges commonly reported in clinical and research use. They are kept as a range rather than a single figure because that is what the sources actually support — a half-life varies with route, formulation and the person.

These are not citations, and this page is not a review of the evidence. Where a number matters to you, follow the database links above and read the source. We say so plainly rather than dressing a compiled reference up as one.

Nothing on this page has been reviewed by a named clinician. It is a reference for people already tracking a protocol, not a recommendation to start one.

Published by Creative Images LLC · Last updated · Corrections: support